Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Initiation of antiretroviral therapy

Initiation of antiretroviral therapy Anton Pozniak Purpose of review Introduction Until there is a therapy or a vaccine that can eradicate HIV The marked decline in annual AIDS-related mortality infection, it is important to continue debating the issues of and morbidity over the past 10 years is largely accredited when and how to use the many antiviral agents licensed as to the widespread introduction of highly active antire- initial treatment since there remain many areas of troviral therapy (HAART) in 1995. The Antiretroviral uncertainty. Therapy Cohort Collaboration found a decline in Recent findings incidence of AIDS-defining events among 12 574 anti- Early initiation of treatment may be beneficial in terms of HIV retroviral-naive individuals from 129.3 per 1000 person- progression but it has to be weighed against the risks of years in the first 3 months after starting HAART to 13.2 in adverse drug side effects and complications. In first-line the third year after starting HAART (P< 0.001) [1 ]. treatment the choice of nucleoside backbones has become limited due to the availability of once a day combined The most common cause of death pre-HAART was formulations which have excellent short and long-term AIDS opportunistic infections, but in the HAART era side-effect profiles. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Initiation of antiretroviral therapy

Current Opinion in HIV and Aids , Volume 1 (5) – Sep 1, 2006

Loading next page...
 
/lp/wolters-kluwer-health/initiation-of-antiretroviral-therapy-sa5u5aG8Wp

References (83)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/01.COH.0000239852.22614.b1
pmid
19372839
Publisher site
See Article on Publisher Site

Abstract

Anton Pozniak Purpose of review Introduction Until there is a therapy or a vaccine that can eradicate HIV The marked decline in annual AIDS-related mortality infection, it is important to continue debating the issues of and morbidity over the past 10 years is largely accredited when and how to use the many antiviral agents licensed as to the widespread introduction of highly active antire- initial treatment since there remain many areas of troviral therapy (HAART) in 1995. The Antiretroviral uncertainty. Therapy Cohort Collaboration found a decline in Recent findings incidence of AIDS-defining events among 12 574 anti- Early initiation of treatment may be beneficial in terms of HIV retroviral-naive individuals from 129.3 per 1000 person- progression but it has to be weighed against the risks of years in the first 3 months after starting HAART to 13.2 in adverse drug side effects and complications. In first-line the third year after starting HAART (P< 0.001) [1 ]. treatment the choice of nucleoside backbones has become limited due to the availability of once a day combined The most common cause of death pre-HAART was formulations which have excellent short and long-term AIDS opportunistic infections, but in the HAART era side-effect profiles.

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Sep 1, 2006

There are no references for this article.